Glucocorticoide: Stellenwert in der Therapie der Vaskulitis
Authors:
- 1 April 2005
- journal article
- abstracts
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 64 (3) , 155-161
Abstract
Only the modification of natural steroids in the middle of the last century gave insights into the structural requirements for the biological activity of the glucocorticoids (GC). While the delta-4,3-keto-11-beta, 17-alpha,21-trihydroxyl configuration is needed for the GC-activity, an artificial additional double binding in position 1 and 2 lead to a four fold increase of the GC-activity. Of the artificial GC, prednisolone is the most frequently used compound and essential in the therapy of vasculitis today. Dosage, duration and way of application depend on the diagnosis, disease stage, -extend as well as -activity. Considering the use and side-effects of the GC, experiences from cohort-studies of the late 80-ties help at clinical decision making. For giant cell arteritis (GCA) it was shown, that doses of less then 60 mg/day are needed for the induction of remission. Concerning the visual loss in GCA, time of initiating GC-therapy seems more important than the dosage. In the treatment of ANCA-associated vasculitis therapy with GC, later in combination with cyclophosphamide, lead to a significant reduction of mortality. Due to the fact of an increasing survival rate, therapy-related morbidity becomes a more and more important issue. There is a proven correlation between the dosage respectively duration of the GC-therapy and the risk of GC-associated side-effects, especially the incidence of severe infections. This article gives a short review of the present data of the role of GC in the treatment of vasculitis.Keywords
This publication has 43 references indexed in Scilit:
- Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomesArthritis Care & Research, 2003
- Recovery of visual function in patients with biopsy-proven giant cell arteritisOphthalmology, 2003
- A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritisArthritis & Rheumatism, 2002
- Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumaticaArthritis & Rheumatism, 1997
- Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras.Journal of Clinical Investigation, 1997
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- Lack of Superiority of Steroids Plus Plasma Exchange to Steroids Alone in the Treatment of Polyarteritis Nodosa and Churg‐Strauss SyndromeArthritis & Rheumatism, 1992
- Stopping steroids in polymyalgia rheumatica and giant cell arteritis.BMJ, 1990
- Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.Annals of the Rheumatic Diseases, 1989
- Infectious complications of cyclophosphamide treatment for vasculitisArthritis & Rheumatism, 1989